Cipla Receives U.S. FDA Approval for Generic Advair Diskus®

Cipla Limited has received U.S. Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for generic Advair Diskus® (fluticasone propionate and salmeterol inhalation powder) in all three strengths. This therapeutically equivalent product is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD), and its approval is a significant milestone for Cipla's respiratory capabilities in the U.S.